Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025

Structure Therapeutics Reports Second Quarter

2025 Financial Results and Recent Highlights

Topline data from oral small molecule GLP-1

receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts

Aleniglipron clinical development program expanded

to optimize competitive positioning and Phase 3 program

Oral small molecule amylin

receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025

Strong financial position with cash, cash equivalents

and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through

SAN FRANCISCO, August 6, 2025-

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule

therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the second quarter ended June 30,

2025, and provided a business update.

"The ACCESS and ACCESS II studies for aleniglipron, our once-daily

oral small molecule GLP-1 program, remain on track for topline data readouts by the end of the year," said Raymond Stevens, Ph.D.,

CEO of Structure Therapeutics. "With our continued confidence in aleniglipron's profile, we have initiated additional supplementary

studies to ensure we are well positioned for Phase 3 and to maximize the therapeutic and competitive potential of this program. By the

end of 2025, we also plan to initiate the Phase 1 study of ACCG-2671, which we believe represents the most advanced oral small molecule

amylin agonist in development. As the obesity field shifts towards combinability of multiple targets and long-term weight loss maintenance,

we are excited to lead the way with a highly scalable pipeline of oral small molecule medicines designed to address the substantial unmet

needs in obesity management and related metabolic diseases."

Recent and Upcoming Milestones

Aleniglipron (GSBR-1290)- Oral Small Molecule Selective Glucagon-Like

Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight

Ongoing ACCESS and ACCESS II Studies

The fully enrolled ACCESS and ACCESS II studies are on track for topline

36-week data readouts by year-end 2025.

Expanded Data Collection from ACCESS and ACCESS II Studies

Structure Therapeutics has implemented

extensions to the ongoing ACCESS and ACCESS II studies:

- Following the initial 36-week efficacy evaluation, patients will now continue on their assigned dose to 44 weeks, which allows

for collection of an additional eight weeks of double-blinded safety, tolerability, and efficacy data in the study. Overall, this extension

will provide additional longer-term data in the two potentially higher dose arms of 180 mg and 240 mg. Per protocol and as previously

planned, a formal unblinded efficacy assessment at 36 weeks is expected by year-end 2025.

Three Additional Aleniglipron Studies

Structure Therapeutics is also conducting three new aleniglipron clinical

studies as planned that will generate additional data to competitively position aleniglipron and further support the design of the Phase

Oral Small Molecule Amylin Receptor Agonists for the Treatment of

Obesity or Overweight with Comorbidities

Oral Small Molecule Metabolic Pipeline and Potential Combinations:

Oral Small Molecule Lysophosphatidic Acid 1 Receptor (LPA1R) Program

for Idiopathic Pulmonary Fibrosis (IPF)

Structure Therapeutics has successfully finished a Phase 1 single and

multiple ascending dose clinical study of LTSE-2578, an oral small molecule antagonist that targets the LPA1R for the treatment of IPF.

In the study there was no evidence of any dose-dependent LTSE-2578-related adverse events, including clinical, laboratory and electrocardiogram

recordings. No SAEs were observed in the study.

Second Quarter 2025 Financial Highlights

Cash Position: Cash, cash equivalents and short-term investments

totaled $786.5 million on June 30, 2025. The Company expects its current cash, cash equivalents and short-term investments to fund

projected operations and key clinical milestones through at least 2027. For aleniglipron, this includes the ongoing ACCESS and ACCESS

II studies, extension studies, and the three new clinical studies announced, but excludes Phase 3 registrational studies.

Research and Development (R&D) Expenses: R&D expenses

for the second quarter of 2025 were $54.7 million, as compared to $22.1 million for the same period in 2024. The increase in R&D expenses

was primarily due to increases related to pre-clinical research and development expenses, clinical trial costs and personnel-related expenses

due to an increase in headcount to support the advancement of our GLP-1R franchise including aleniglipron.

General and Administrative (G&A) Expenses: G&A expenses

for the second quarter of 2025 were $15.7 million, as compared to $11.3 million for the same period in 2024. The increase in G&A expenses

was primarily due to increases in employee expenses as we expanded our infrastructure to drive and support the growth in our operations

as a publicly-traded company.

Net Loss: Net loss for the second quarter of 2025 totaled $61.7

million, with non-cash share-based compensation expense of $7.5 million, compared to $26.0 million for the second quarter of 2024 with

non-cash share-based compensation expense of $4.2 million.

About Structure Therapeutics

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical

company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions

with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established

a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to

surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.

For additional information, please visit www.structuretx.com.

Forward Looking Statements

This press release contains "forward-looking statements"

within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements

other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation,

statements concerning: the Company's future plans and prospects; the expected timing of topline data from the ACCESS and ACCESS

II studies; the planned initiation of the ACCG-2671 Phase 1 study and the timing thereof; the Company's anticipated cash runway

and uses of cash; the belief that ACCG-2671 represents one of the most advanced oral small molecule amylin agonists in development; the

belief that the Company is well positioned to lead with a highly scalable pipeline of oral small molecule medicines designed to address

the substantial unmet needs in obesity management and related metabolic diseases; the potential benefits of expanding data collection

from the ACCESS and ACCESS II studies; the Company's plans to conduct three new aleniglipron studies, including the study design

and timing thereof; the expected timing for declaring a second amylin receptor agonist oral small molecule development candidate; and

the expected timing for long term chronic GLP-toxicology studies of ANPA-0073;; and any expectations regarding the safety, efficacy or

tolerability of aleniglipron, ACCG-2671, ANPA-0073, LTSE-2578 and other candidates under development. In addition, when or if used in

this press release, the words and phrases "anticipated," "believe," "expect," "may," "on

track," "plan," "potential," "suggests," "to be," "to begin," "will,"

and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements

are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking

statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that

actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied

in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks

and uncertainties related to the results from earlier clinical studies not necessarily being predictive of future results; potential delays

in the commencement, enrollment and completion of the Company's planned clinical studies, the Company's ability to advance

aleniglipron, ACCG-2671, ANPA-0073, LTSE-2578, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize

the Company's therapeutic candidates; competitive products or approaches limiting the commercial value of the Company's product

candidates; the timing and results of preclinical and clinical studies; the Company's ability to fund development activities and

achieve development goals; the Company's reliance on third parties, including clinical research organizations, manufacturers, suppliers

and collaborators, over which it may not always have full control; the impact of any global pandemics, inflation, tariffs, changes in

monetary and fiscal policy, supply chain issues, rising interest rates, future bank failures and other macroeconomic factors on the Company's

business, its ability to protect its intellectual property and other risks and uncertainties described in the Company's filings

with the Securities and Exchange Commission (SEC), including the Company's latest Quarterly Report on Form 10-Q and future